“o.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
LOS ANGELES, September 2, 2020 /PRNewswire/- Science 37, industry leader in decentralized clinical trials, announced the appointment of industry veteran John Hubbard, Ph.D., CPF on its Board of Directors.
Dr. Hubbard brings more than 3 decades of experience in various senior management positions in key industry organizations. Most recently, he was President and CEO of Bioclinica, a leading provider of clinical medical imaging and generation facilities. The corporation completed 4 strategic acquisitions that strengthened and expanded its clinical development functions. Bioclinica doubled in size and expanded its visitor base to reach the 100 most sensible pharmaceutical corporations and the 10 most sensible contract study organizations. Prior to Bioclinica, Dr. Hubbard was Senior Vice President and Worldwide Director of Development Operations at Pfizer. Early in his career, Dr. Hubbard helped drive ICON plc’s exponential expansion as President of the Global Division of Clinical Study Facilities.
“We are pleased that John is on the Board of Directors,” Robert C said.Faulkner, President of science council 37.” With more than 30 years of leadership in the biopharmaceutical and pharmaceutical sectors, John provides a strategic vision and direction to enable the expansion of science 37.Their delight in creating organizations and capitalizing on market prospects is especially valuable, as we seek to make virtual trials the new truth for sponsors and patients.”
“John joins the Board of Directors of Science 37 at an ideal time,” said David Coman, executive director of Science 37.”As we continue to drive our growth, John’s delight with corporations on a similar track record will bring ordinary prices and advice.We look forward to leveraging your experience in the future.”
Dr Hubbard said: “I am very happy to join the Board of Science 37 during this critical era of biopharmaceutical progression.Today, more than ever, we will have to apply principles of innovation, complex generation and telemedicine to drive the progression of biopharmaceuticals.”Finding a safe and effective vaccine to treat COVID-19 has been a catalyst for our industry to reconsider the paradigm of drug progression.Science 37’s philosophy, operations and generation are adopting this new technique and I look forward to running with Rob, David and our Board of Directors as we expand Science 37 and provide assistance to patients with greater access to new, cutting-edge therapies.”
Dr. Hubbard is recently a board member of Advarra and Agile Therapeutics, president of Signant Health and a founding member of the board of transCelerate Biopharma Inc., a leading consortium in the biopharmaceutical industry.Hubbard holds a bachelor’s degree in science from Santa Clara University with a Doctorate from the University of Tennessee and a postdoctoral fellow from the NIH at the Center for Health Sciences at the University of Texas, San Antonio.
In Science 37, Science 37 makes the promise of virtual testing a new reality.By interacting with patients from the comfort of their own home, we provide access to patients who will never be able to succeed through classic site-based models.Science 37 has conducted more decentralized interventional trials than any other company, a vast network of telemedicine researchers and fitness nurses, backed by the industry’s most comprehensive, fully incorporated and a decentralized clinical trial platform.Learn more about Science 37 and stick to Science 37 on Twitter, LinkedIn, and Facebook.
View content to download media: http://www.prnewswire.com/news-releases/john-hubbard-phd-joins-science-37-board-of-directors-301122590.html
SOURCE Science 37